Results 41 to 50 of about 560,791 (351)

MDM2-Mediated Ubiquitination of Angiotensin-Converting Enzyme 2 Contributes to the Development of Pulmonary Arterial Hypertension

Circulation, 2020
Supplemental Digital Content is available in the text. Background: Angiotensin-converting enzyme 2 (ACE2) converts angiotensin II, a potent vasoconstrictor, to angiotensin-(1–7) and is also a membrane protein that enables coronavirus disease 2019 (COVID ...
Hui Shen, Jiao Zhang, Chen Wang, P. Jain, M. Xiong, Xin Shi, Yuyang Lei, Shanshan Chen, Qian Yin, P. Thistlethwaite, Jian Wang, Kaizheng Gong, Z. Yuan, J. Yuan, J. Shyy   +14 more
semanticscholar   +1 more source

Glucocorticoids for treating paediatric pulmonary hypertension: A novel use for a common medication [PDF]

, 2017
Laboratory investigations have shown the role of inflammation in the pathogenesis of pulmonary hypertension and improvement after anti-inflammatory drugs.
Aggarwal, Manish, Grady, Ronald M
core   +2 more sources

Pregnancy in pulmonary arterial hypertension [PDF]

European Respiratory Review, 2016
Despite advanced therapies, maternal mortality in women with pulmonary arterial hypertension (PAH) remains high in pregnancy and is especially high during the post-partum period. However, recent data indicates that morbidity and mortality during pregnancy and after birth have improved for PAH patients.
Karen M. Olsson, Richard N. Channick
openaire   +4 more sources

Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension.

Antioxidants and Redox Signaling, 2020
Endothelial-to-Mesenchymal transition (EndMT) is a process which encompasses extensive transcriptional reprogramming of activated endothelial cells leading to a shift towards mesenchymal cellular phenotypes and functional responses. Initially observed in
A. Gorelova, M. Berman, I. Al Ghouleh
semanticscholar   +1 more source

Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. [PDF]

, 2014
The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascular (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was influenced by CV risk factors in PAH patients. We studied
Charalampopoulos, A, Connolly, SB, Davies, RJ, Gibbs, JS, Gin-Sing, W, Grapsa, J, Howard, LS, Nihoyannopoulos, P, Tzoulaki, I, Wilkins, MR   +9 more
core   +1 more source

The arterial load in pulmonary hypertension [PDF]

European Respiratory Review, 2010
The anatomical differences between the pulmonary and systemic arterial system are the main cause of the difference in distribution of compliance. In the pulmonary arterial system compliance is distributed over the entire arterial system, and stands at the basis of the constancy of the RC-time.
Saouti, N., Westerhof, N., Postmus, P.E., Vonk Noordegraaf, A.   +3 more
openaire   +4 more sources

Development of a personalized visualization and analysis tool to improve clinical care in complex multisystem diseases with application to scleroderma

Arthritis Care &Research, Accepted Article.
Background In complex diseases, it is challenging to assess a patient's disease state, trajectory, treatment exposures, and risk of multiple outcomes simultaneously, efficiently and at the point of care. Methods We developed an interactive patient‐level data visualization and analysis tool (VAT) that automates illustration of a scleroderma patient's ...
Ji Soo Kim, John Scott, Lauren Fisher, Lauren N. Smith, Willie Stewart, Adrianne Woods, Rob Smithwright, Diane Koher, Parastoo Aslanbeik, Aalok B. Shah, Brad Tibbils, Samantha I. Pitts, Ayse P. Gurses, Yushi Yang, Ana‐Maria Orbai, Antony Rosen, Laura K. Hummers, Scott L. Zeger, Ami A. Shah   +18 more
wiley   +1 more source

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension

European Respiratory Journal, 2017
Current European guidelines recommend periodic risk assessment for patients with pulmonary arterial hypertension (PAH). The aim of our study was to determine the association between the number of low-risk criteria achieved within 1 year of diagnosis and ...
A. Boucly, J. Weatherald, L. Savale, X. Jaïs, V. Cottin, G. Prévôt, F. Picard, P. De Groote, M. Jevnikar, E. Bergot, A. Chaouat, C. Chabanne, A. Bourdin, F. Parent, D. Montani, G. Simonneau, M. Humbert, O. Sitbon   +17 more
semanticscholar   +1 more source

Obesity, estrogens and adipose tissue dysfunction – implications for pulmonary arterial hypertension

Pulmonary Circulation, 2020
Obesity is a prevalent global public health issue characterized by excess body fat. Adipose tissue is now recognized as an important endocrine organ releasing an abundance of bioactive adipokines including, but not limited to, leptin, adiponectin and ...
K. Mair, R. Gaw, M. MacLean
semanticscholar   +1 more source

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension. [PDF]

, 2018
Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial hypertension ...
Ayon, Ramon J, Balistrieri, Angela, Black, Stephen M, Chen, Jiwang, Desai, Ankit A, Garcia, Joe GN, Gu, Yali, Makino, Ayako, Rischard, Franz, Song, Shanshan, Tang, Haiyang, Vanderpool, Rebecca, Vinjamuri, Sujana, Wang, Jian, Wang, Ziyi, Wu, Kang, Yuan, Jason X-J, Zhang, Qian, Zhou, Guofei   +18 more
core   +1 more source